Therapeutic Solutions International, Inc. Announces the Appointment of Francesco M Marincola, MD, FACS, to the TSI Scientific Advisory Board
October 21, 2015 09:00 ET
OCEANSIDE, CA — October 21, 2015 — InvestorsHub NewsWire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Francesco M Marincola, MD, FACS, has been appointed to our Scientific Advisory Board.
Dr. Marincola previously held the position of Chief of the Infectious Disease and Immunogenetics Section (IDIS) and Tenured Senior Investigator at the U.S. National Institutes of Health (NIH). He was also Director of the Immunogenetics Program, Department of Transfusion Medicine, Director of the Federation of Clinical Immunology Societies (FOCIS) Center for Excellence and Co-Director of the Trans-NIH Center for Human Immunology.
Dr. Marincola received his MD summa cum laude from the University of Milan and his surgery training from Stanford University. Dr. Marincola is the second most cited scientist in the field of melanoma during the last ten years, with 55 papers cited 3,704 times to date. His research interest is primarily translational and focuses on the development of strategies for the dynamic study of patients’ response to therapies. His approach has deepened understanding of the mechanisms leading to rejection of tumors, allograft, graft versus host disease and leading to the development of autoimmunity.
“With the appointment of Dr. Marincola to our Scientific Advisory Board who now joins Dr. Michael G. Agadjanyan, Dr. Santosh Kesari, and Dr. Harry Lander, we truly have a world class team of scientists to identify and discuss significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its development programs and research activities” said Timothy Dixon, President and CEO of Therapeutic Solutions.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.